noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Calidi Biotherapeutics Inc.

Registration Statement - Additional Securities (Form S-3MEF)
REalloys Inc.

Registration Statement - Additional Securities (Form S-3MEF)
Alaska Department of Military &[...]

Arctic Connect validates HF communication across Alaska

Healthcare

Amgen Inc.

01/24/2025 | Press release | Distributed by Public on 01/24/2025 12:02

Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products

We are pleased to have reached resolution of our patent infringement litigation related to Celltrion's denosumab biosimilar products. The court's order issued today (January 24, 2025), holds the claims of Amgen's U.S. patents asserted against Celltrion valid, enforceable and infringed by Celltrion's denosumab biosimilars in the United States. In addition, Amgen and Celltrion have reached a confidential settlement that allows Celltrion to launch its biosimilar products in the U.S. as early as June 1, 2025. Specific financial terms remain confidential. The settlement and court decision affirm the strength of Amgen's patent rights for denosumab.

Amgen Inc. published this content on January 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 24, 2025 at 18:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format